title: Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
abstract: The management of extensive, recurrent limb desmoid tumors is extremely difficult. The failure of multimodality treatments, such as repeated resections, radiotherapy, systemic chemotherapy, or endocrine manipulations, can end up with multilating surgery or even amputation, similar problems sometimes encountered in soft tissue sarcoma of the limbs. The high rate of limb salvage achieved by isolated limb perfusion (ILP) with tumor necrosis factor (TNF) and melphalan for extensive, high-grade soft tissue sarcoma led us to implement this modality in difficult cases of limb desmoids.
  
  
  
  During a 4-year period, 6 patients aged 14 to 52 years were treated. All were significantly symptomatic and candidates for amputation or mutilating surgery. Five had lower and one had upper limb lesions. Two had multifocal disease. At ILP, 3 to 4 mg TNF and 1 to 1.5 mg/kg melphalan were delivered during a 90-minute period. One patient had a double perfusion. All patients underwent definitive resective operation 6 to 8 weeks after perfusion.
  
  
  
  No systemic complications were observed, and local complications included reversible skin redness and blisters. Response rate was 83% with 33% (2 of 6) complete response and 50% (3 of 6) partial response. In 1 patient less than 50% regression was observed. Limb salvage rate was 100%; even the patient with stabilization of disease could be locally resected. Local recurrence during a follow-up period of 7 to 55 months (median 45 months) occurred in 2 patients at 8 and 24 months, respectively; the first underwent amputation, whereas for the second a wide excision was possible.
  
  
  
  ILP with TNF and melphalan can be used as a limb preservation modality in patients with recurrent desmoids and significant symptoms who would otherwise require multilating surgery to control their neoplasm.
authors.affiliation: Department of Surgery B, Tel Aviv Sourasky Medical Center, Israel.
authors.forename: D
authors.initials: D
authors.lastname: Lev-Chelouche
authors.forename: S
authors.initials: S
authors.lastname: Abu-Abeid
authors.forename: R
authors.initials: R
authors.lastname: Nakache
authors.forename: J
authors.initials: J
authors.lastname: Issakov
authors.forename: Y
authors.initials: Y
authors.lastname: Kollander
authors.forename: O
authors.initials: O
authors.lastname: Merimsky
authors.forename: I
authors.initials: I
authors.lastname: Meller
authors.forename: J M
authors.initials: JM
authors.lastname: Klausner
authors.forename: M
authors.initials: M
authors.lastname: Gutman
mesh_terms: D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005121:Extremities / Q000098:blood supply; D005260:Female; D018222:Desmoid Tumors / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010477:Perfusion; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D018906:Antineoplastic Agents, Alkylating; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan